Your browser doesn't support javascript.
loading
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.
Rochau, Ursula; Stojkov, Igor; Conrads-Frank, Annette; Borba, Helena H; Koinig, Karin A; Arvandi, Marjan; van Marrewijk, Corine; Garelius, Hege; Germing, Ulrich; Symeonidis, Argiris; Sanz, Guillermo F; Fenaux, Pierre; de Witte, Theo; Efficace, Fabio; Siebert, Uwe; Stauder, Reinhard.
Affiliation
  • Rochau U; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.
  • Stojkov I; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.
  • Conrads-Frank A; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.
  • Borba HH; Department of Pharmacy, Pharmaceutical Sciences Postgraduate Research Program, Federal University of Paraná, Curitiba, Brazil.
  • Koinig KA; Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.
  • Arvandi M; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.
  • van Marrewijk C; Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands.
  • Garelius H; Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden.
  • Germing U; Department of Hematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany.
  • Symeonidis A; Department of Internal Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece.
  • Sanz GF; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Fenaux P; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • de Witte T; Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France.
  • Efficace F; Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud university medical center, Nijmegen, the Netherlands.
  • Siebert U; Health Outcomes Research Unit, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA), Rome, Italy.
  • Stauder R; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.
Br J Haematol ; 191(3): 405-417, 2020 11.
Article in En | MEDLINE | ID: mdl-32410281
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes Type of study: Systematic_reviews Limits: Humans Language: En Journal: Br J Haematol Year: 2020 Document type: Article Affiliation country: Austria Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes Type of study: Systematic_reviews Limits: Humans Language: En Journal: Br J Haematol Year: 2020 Document type: Article Affiliation country: Austria Country of publication: United kingdom